Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Estradiol Valerate and Dienogest 2 mg/2 mg
NCT05332106Phase 1Completed
- Sponsor
- Laboratorios Andromaco S.A.
- Start
- Mar 2022
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of estradiol valerate and dienogest in postmenopause (2 arms), sponsored by Laboratorios Andromaco S.A. Primary endpoints: Area under the plasma concentration-time curve from time zero to 72 hours, Maximum plasma concentration at 72 hours and 1 more. Started Mar 2022; status: completed.
02
Drugs
estradiol valeratedienogest
03
Conditions
postmenopause
Beyond the preview
Go deeper on NCT05332106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05332106.